智通财经APP获悉，复宏汉霖(02696)现涨超4%，截至发稿，涨4.24%，报17.7港元，成交额365.55万港元。
消息面上，复宏汉霖公告，公司自主研发的Perjeta （帕妥珠单抗）生物类似药候选药HLX11的生物制品许可申请（BLA）获美国食品药品管理局（FDA）受理。据悉，HLX11是公司自主研发的帕妥珠单抗生物类似药，拟用于HER2阳性早期乳腺癌的新辅助/辅助治疗、HER2阳性转移性乳腺癌的治疗及与原研药药品标签相符的其他适应症。
值得注意的是，1月26日，复宏汉霖宣布，公司两项创新药抗PD-1单抗H药汉斯状和创新型抗HER2单抗HLX22的最新研究结果在2025年美国临床肿瘤学会胃肠道肿瘤研讨会（ASCOGI）上以壁报形式发布。据悉，H药汉斯状为复宏汉霖自主研发的重组人源化抗PD-1单抗注射液，也是全球首个获批一线治疗小细胞肺癌的抗PD-1单抗；HLX22为复宏汉霖自AbClon,Inc.许可引进、并后续自主研发的靶向HER2的创新型单克隆抗体。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.